Cliff Asness’s TScan Therapeutics TCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.36K Buy
+13,866
New +$9.6K ﹤0.01% 4056
2025
Q3
– Sell
-22,438
Closed -$32.5K – 3590
2025
Q2
$32.5K Buy
+22,438
New +$32.4K ﹤0.01% 3262
2024
Q4
– Sell
-12,913
Closed -$64.3K – 2951
2024
Q3
$64.3K Buy
+12,913
New +$77.9K ﹤0.01% 2693

Other funds holding TCRX

Cliff Asness's TCRX Position: Q3 2026 in Review

Cliff Asness opened a new position in TScan Therapeutics (TCRX) in Q3 2026: 13,866 shares worth $4.36K. The stake represents ﹤0.01% of the portfolio and ranks #4056 among its holdings. This is a return to the name: Cliff Asness previously reported a position in TCRX as recently as Q2 2025.

Cliff Asness first reported a position in TCRX in Q3 2024 and has held it in 3 quarters since. The position peaked at $64.3K in Q3 2024. 51 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.

  • Cliff Asness held 13,866 shares of TScan Therapeutics worth $4.36K as of Q3 2026.
  • TScan Therapeutics was a new Cliff Asness position in Q3 2026.
  • TScan Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q3 2026, its #4056 holding.
  • Cliff Asness first reported a position in TScan Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Cliff Asness's TScan Therapeutics position peaked at $64.3K in Q3 2024.
  • 51 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.